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unidentified bright objects/T2 hyperintensities on MRI 
scanning, carotid artery aneurysms) have been seen in 
an unusually high number of patients. 
Frequent bony abnormalities are common in HIE. 
The frequency of pathologic fractures in the population 
reported by Grimbacher et al was 58%. Although the 
general mechanism for these abnormalities is unknown, 
Leung et al. have demonstrated increased in vitro bone 
resorption by monocytes from patients with HIE. 
The syndrome is defined by marked elevations of IgE 
(>2000 IU/ml), with levels of more than 50,000 IU/ml 
reported. White blood cell counts are typically in the 
normal range, but have been reported to range from 
60,000 to 1700 per microliter. Mild to moderate 
eosinophilia is the rule, although occasional patients 
do not show this. There is no correlation between IgE 
levels and degree of eosinophilia or clinical disease. 
Mucocutaneous candidiasis with involvement of mouth, 
vagina, intertriginous areas, fingernails, and toenails 
affects about 50% of patients with HIE. High-dose 
prolonged intravenous antibiotics are required for 
eradication of infection. Empirical acute coverage should 
consider S. aureus, H. in@enzae, and S. pneumoniae. 
The former two organisms account for the majority of 
acute infections. Colonization of pneumatoceles and 
bronchiectatic lung with Pseudomonas aeruginosa and 
Aspergillus species can be especially problematic. The 
role of prophylactic antibiotics has not been rigorously 
investigated in this setting but there is general consensus 
for their use. Most investigators direct coverage at S. 
aureus with a synthetic penicillin. 
A scoring system has been devised to aid in the formal 
diagnosis of HIE patients. 
Table 1. Findings in HIES 
Eczema 
Characteristic facies (>16y) 
Skin boils 
Pneumonias 
Mucocutaneous candidiasis 
Lung cysts 
Scoliosis (>16y) 
Delayed dental exfoliation 
Pathologic fractures 
Adapted from Grimbacher et al, 1999 
100% 
100% 
87% 
87% 
a3 96 
77% 
76% 
72% 
57% 
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Conventional allogeneic hematopoietic stem cell trans- 
plantation (HSCT) relies on maximally tolerated doses 
of systemic chemoradiation both to eradicate cancer and 
to achieve host immunosuppression. The allografts then 
act to rescue patients from treatment-induced marrow 
aplasia and contribute graft-vs.-tumor effects of un- 
certain magnitude. Associated toxicities have limited 
treatment with HSCT to younger, medically fit patients 
with therapies administered on specialized hospital 
wards. 
This age restriction has excluded most patients with 
myeloid leukemias and B cell malignancies from trans- 
plantation. In an effort to address this limitation, we 
have developed a nonmyeloablative transplant approach 
in which the burden of tumor eradication has been 
shifted from cytotoxic agents to the graft-vs.-tumor 
effects. In studies using a large randombred canine 
model, we replaced the intense conditioning regimens 
customarily used for host immunosuppression in HSCT, 
and instead optimized immunosuppression with a 
combination of mycophenolate mofetil and cyclosporine 
given for a short period of time post transplantation. 
This served not only to control serious graft-versus-host 
disease (GVHD) but, as importantly, to reduce the 
magnitude of the host-versus-graft reaction. The clinical 
conditioning regimen currently used consists of only 
2 Gy of total body irradiation (TBI) and fludarabine. 
Preliminary clinical results in nearly 450 patients have 
shown the nonmyeloablative regimen used was safe and 
minimally toxic. The typical side effects of conventional 
HSCT such as alopecia, pancytopenia, and transfusion 
dependency were not encountered. Consequently, 57% 
of eligible patients were treated entirely as outpatients, 
with others having relatively short hospitalizations. 
The relatively short period of neutropenia has 
resulted in fewer bacteremias during the first 30 days 
after transplant compared to conventional transplant 
recipients (9% vs. 27%; p=O.Ol). Also, during the first 
100 days after transplant, high-risk nonmyeloablative 
transplant recipients had significantly less cytome- 
galovirus viremia and disease compared to conventional 
transplant recipients (p=O.Ol), though by 1 year after 
transplant the overall incidence of cytomegalovirus 
disease was comparable between the 2 groups. The 
onset of cytomegalovirus disease was significantly 
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delayed among nonmyeloablative recipients (p=O.O2), 
presumably a result of the initial mixed host/donor 
lymphoid chimerism. Most HLA-matched related 
recipients had stable engraftment despite using only 2 
Gy TBI conditioning. An initially observed 17% graft 
rejection rate was reduced to 3% by the addition of 
three doses of Audarabine immediately preceding TBI. 
This has allowed sustained engraftment also with HLA- 
identical unrelated HSCT. Approximately half of the 
patients experienced acute GVHD. Though GVHD 
appeared mostly to be of moderate severity, we 
extended the period of postgrafting immunosuppression 
from 35 days to now a minimum of 84 days after 
transplant in order to reduce the risk of GVHD. The 
optimal duration of postgrafting immunosuppression 
still remains to be determined. The initially observed 
mixed donor-host hematopoietic chimerism was un- 
stable in most patients, progressing to full-donor 
chimerism. Impressive antitumor responses have been 
seen with complete remissions in 66% of those patients 
who had measurable disease before transplant. Of note, 
attainment of complete remission might take months, 
and in some cases, exceeded 1 year. The durability of 
these remissions is still unknown given that the longest 
follow-up is only 4 years. The nonmyeloablative trans- 
plant approach has now also been successfully applied 
to patients with nonmalignant diseases, such as sickle cell 
anemia, paroxysmal nocturnal hemoglobinuria and 
others. In animal models, nonmyeloablative transplan- 
tation has been used to induce tolerance to solid organ 
grafts. 
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The mucosal surface area of an adult individual amounts 
to some 400 m?. This extensive and generally quite 
vulnerable epithelial barrier is protected by numerous 
innate defence mechanisms that cooperate intimately 
with a local adaptive immune system. Its most promin- 
ent feature is an abundance of supepithelial plasma cells 
and B-cell blasts (collectively called immunocytes), 
constituting at least 80% of all antibody-forming cells of 
the body. These local immunocytes produce mainly 
dimeric IgA (dIgA) with incorporated J chain. 
Facing the large host of environmental challenges, 
specific mucosal immunity has developed two strategies: 
(i) immune exclusion performed by secretory antibodies 
(SIgA and SIgM), mainly to inhibit colonization of 
pathogenic microorganisms and penetration of harmful 
antigens; and (ii) immunosuppression to avoid local and 
peripheral hypersensitivity towards innocuous sub- 
stances bombarding the mucosal surfaces. In the gut, the 
latter phenomenon is called oral tolerance; it apparently 
involves several down-regulatory mechanisms and 
explains why most individuals show no adverse immune 
reactions against persistent contact with food proteins 
and the normal microbial flora. 
Immune exclusion depends on an ingenious co- 
operation between the enormous mucosal B-cell system 
and a transmembrane epithelial glycoprotein called 
secretory component (SC), or the polymeric Ig receptor 
(pIgR). This is quantitatively the most important 
receptor of the immune system because it is responsible 
for external transport of large amounts of locally pro- 
duced dIgA and pentameric IgM. The pIgR shows high 
and selective affinity for these two ligands because of 
their incorporated J chain.The epithelial receptor belongs 
to the Ig supergene family and can be upregulated by 
various cytokines, particularly interferon- and inter- 
leukin-4 (IL-4) derived from activated T cells as well as 
IL-1 and TNF- from macrophages. In this way, the 
secretory immune system can be modulated according 
to the intensity of local immune responses. 
During a variable period after birth, both immune 
exclusion and oral tolerance are poorly developed; 
appropriate generation of the underlying network of 
regulatory mechanisms depends both on the establish- 
ment of a normal microbial flora and on the introduction 
of dietary antigens (timing and dose). Breast-feeding 
is immunologically important during this vulnerable 
period, not only as a natural ‘substitution therapy’ for 
the lacking secretory antibodies but apparently also by 
its immune-modulating propertiesThe infant’s secretory 
immune responses are initially dominated by SIgM, but 
after 1 to 2 months SIgA usually predominates, although 
there are large individual variations in the development 
of mucosal immunity. 
Mucosal defence provided by dIgA/SIgA is more 
favourable than that provided by pentameric IgM/SIgM 
because (a) dIgA more easily gains access to the 
basolaterally expressed epithelial pIgR and is therefore 
efficiently transported to the lumen; (b) SIgA is a 
particularly stable antibody class and is therefore well 
suited to perform immune exclusion; (c) dIgA generally 
functions in a noninflammatory manner and may be 
involved in epithelial clearance of soluble antigens from 
the mucosa as well as intraepithelial virus neutralization 
with no cytolytic side-effect; (d) dIgA avidly binds to 
Fc-R on phagocytes and may normally dampen their 
proinflammatory potential but enhance phagocytosis; 
and (e) dIgA and especially SIgA (and SC on a solid 
phase) can efficiently activate eosinophils and thus 
enhance their proinflammatory potential in situations 
where immune exclusion fails, such as in parasitic 
infestations. Our recent construction of pIgR/SC knock- 
out mice has substantiated the importance of secretory 
immunity for mucosal homeostasis and defence against 
toxin-producing pathogens. 
In subjects with IgA deficiency, there is regularly a 
compensatory overproduction of SIgM and IgGl in 
intestinal mucosa; this probably explains why they have 
relatively few problems with gut infections. In contrast, 
